Plethico Pharmaceuticals, Indore based Rs 325 crore plus pharma company, has achieved strong performance during the year ended September 2006. Its standalone net profit went up sharply by 53.3 per cent to Rs 86.03 crore from Rs 56.13 crore in the previous year.
The company's net sales increased by 46.5 per cent to Rs 328.42 crore from Rs 224.12 crore. The annual earning per share, after considering the rise in the equity capital resulted from the public issue, worked out to Rs 26.93. The company declared equity dividend of 25 per cent.
The earning before interest, depreciation and taxation also increased by 47.5 per cent to Rs 99.41 crore from Rs 67.38 crore in the previous year. The company provided Rs 5.43 crore for interest as against Rs 2.92 crore and Rs 5.75 crore for depreciation (Rs 4.96 crore in the previous year).
Plethico's equity capital increased to Rs 34.07 crore during the year ended September 2006 from Rs 7.60 crore on account of public issue. The company spend around Rs 25.86 crore up to September 2006 on different projects. The total cost of these projects is estimated around Rs 117 crore. With collection of huge premium, the company's reserves increased to Rs 409.73 crore from Rs 254.74 crore in the previous year.